{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:11:42Z","timestamp":1789506702842,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128913","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:54:12Z","timestamp":1784073252000},"page":"128913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of antigen and carrier substitution on the molecular weight and immunogenicity of the Pfs230D1\u2013CRM197 malaria transmission-blocking vaccine"],"prefix":"10.1016","volume":"88","author":[{"given":"Puthupparampil V.","family":"Scaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Muratova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Kemanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin Y.A.","family":"Doritchamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn E.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma K.","family":"Barnafo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Narum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Shaligram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gale","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick E.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128913_bb0005","unstructured":"World malaria report 2025: Addressing the threat of antimalarial drug resistance. Geneva: World Health Organization; 2025. [Licence: CC BY-NC-SA 3.0 IGO]."},{"key":"10.1016\/j.vaccine.2026.128913_bb0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"RTS,S Clinical Trials Partnership","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128913_bb0015","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants","volume":"367","author":"RTS,S Clinical Trials Partnership","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128913_bb0020","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128913_bb0025","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128913_bb0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/14760584.2021.1878028","article-title":"Transmission-blocking vaccines: harnessing herd immunity for malaria elimination","volume":"20","author":"Duffy","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128913_bb0035","doi-asserted-by":"crossref","unstructured":"Acquah FK, Adjah J, Williamson KC, Amoah LE. Transmission-blocking vaccines: old friends and new prospects. Infect Immun 2019;87:e00775\u201318. doi:https:\/\/doi.org\/10.1128\/IAI.00775-18.","DOI":"10.1128\/IAI.00775-18"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128913_bb0040","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/14760584.2025.2517720","article-title":"Advances in transmission-blocking vaccines against Plasmodium falciparum and Plasmodium vivax","volume":"24","author":"Tachibana","year":"2025","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128913_bb0045","doi-asserted-by":"crossref","unstructured":"Healy SA, Sagara I, Assadou MH, Katile A, Kone M, Imeru A, Kwan JL, Swihart BJ, Fintzi J, Potter GE, Zeguim\u00e9 A, Dolo A, Diarra B, Narum DL, Rausch KM, MacDonald NJ, Zhu D, Mohan R, Thera I, Morrison RD, Zaidi I, Doritchamou JYA, Sylla D, Hume JCC, Coulibaly MB, Morelle D, Lievens M, Doumbo OK, Duffy PE; Pfs230D1 vaccine team. A vaccine to block Plasmodium falciparum transmission. NEJM Evid 2025 Jul;4(7):EVIDoa2400188. doi:https:\/\/doi.org\/10.1056\/EVIDoa2400188. [Epub 2025 Jun 24].","DOI":"10.1056\/EVIDoa2400188"},{"issue":"34","key":"10.1016\/j.vaccine.2026.128913_bb0050","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1016\/j.vaccine.2020.06.018","article-title":"Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230","volume":"38","author":"Scaria","year":"2020","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128913_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190312","article-title":"Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity","volume":"12","author":"Scaria","year":"2017","journal-title":"PLOS One"},{"issue":"38","key":"10.1016\/j.vaccine.2026.128913_bb0060","doi-asserted-by":"crossref","first-page":"19913","DOI":"10.1074\/jbc.M116.732305","article-title":"Structural and immunological characterization of recombinant 6-cysteine domains of the plasmodium falciparum sexual stage protein Pfs230","volume":"291","author":"MacDonald","year":"2016","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128913_bb0065","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146221","article-title":"Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice","volume":"131","author":"Healy","year":"2021","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128913_bb0070","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/vaccines13060648","article-title":"SARS-CoV-2 receptor binding domain (RBD) protein-protein conjugate induces similar or better antibody responses as spike mRNA in Rhesus macaques","volume":"13","author":"Scaria","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128913_bb0075","article-title":"Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial","volume":"18","author":"Toledo-Roman\u00ed","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.vaccine.2026.128913_bb0080","doi-asserted-by":"crossref","unstructured":"Sagara I, Healy SA, Assadou MH, Kone M, Swihart BJ, Kwan JL, Fintzi J, Sissoko K, Kamate B, Samake Y, Guindo MA, Doucoure M, Niar\u00e9 K, Dolo A, Diarra B, Rausch KM, Narum DL, Jones DS, MacDonald NJ, Zhu D, Gorres JP, Imeru A, Mohan R, Thera I, Zaidi I, Salazar-Miralles F, Duan J, Neal J, Morrison RD, Muratova O, Sylla D, O'Connell EM, Wu Y, Hume JCC, Coulibaly MB, Anderson CF, Traore SF, Doumbo OK, Duffy PE. Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial. Lancet Infect Dis 2023 Nov;23(11):1266\u20131279. doi:https:\/\/doi.org\/10.1016\/S1473-3099(23)00276-1. [Epub 2023 Jul 24].","DOI":"10.1016\/S1473-3099(23)00276-1"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600722X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600722X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:41:14Z","timestamp":1789504874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2600722X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":16,"alternative-id":["S0264410X2600722X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128913","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of antigen and carrier substitution on the molecular weight and immunogenicity of the Pfs230D1\u2013CRM197 malaria transmission-blocking vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128913"}}